These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 12398962)
21. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Zhao SZ; Wentworth C; Burke TA; Makuch RW Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778 [TBL] [Abstract][Full Text] [Related]
22. A retrospective review of the effect of COX-2 inhibitors on blood pressure change. Cho J; Cooke CE; Proveaux W Am J Ther; 2003; 10(5):311-7. PubMed ID: 12975714 [TBL] [Abstract][Full Text] [Related]
23. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Grover SA; Coupal L; Zowall H Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508 [TBL] [Abstract][Full Text] [Related]
24. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. Henderson P JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848 [No Abstract] [Full Text] [Related]
25. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847 [No Abstract] [Full Text] [Related]
26. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
27. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Gibofsky A; Williams GW; McKenna F; Fort JG Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272 [TBL] [Abstract][Full Text] [Related]
28. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Cutts C; LaCaze A; Tett S Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032 [TBL] [Abstract][Full Text] [Related]
29. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Reuben SS; Connelly NR Anesth Analg; 2000 Nov; 91(5):1221-5. PubMed ID: 11049912 [TBL] [Abstract][Full Text] [Related]
30. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772 [TBL] [Abstract][Full Text] [Related]
31. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
32. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Izhar M; Alausa T; Folker A; Hung E; Bakris GL Hypertension; 2004 Mar; 43(3):573-7. PubMed ID: 14744921 [TBL] [Abstract][Full Text] [Related]
33. Are rofecoxib and celecoxib safer NSAIDS? Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599 [TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP; Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224 [TBL] [Abstract][Full Text] [Related]
35. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. Gibofsky A J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424 [TBL] [Abstract][Full Text] [Related]
36. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. Wolfe F; Michaud K; Burke TA; Zhao SZ J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808 [TBL] [Abstract][Full Text] [Related]
37. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Collantes-Estevez E; Fernandez-Perez C Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477 [TBL] [Abstract][Full Text] [Related]
38. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Malmstrom K; Daniels S; Kotey P; Seidenberg BC; Desjardins PJ Clin Ther; 1999 Oct; 21(10):1653-63. PubMed ID: 10566562 [TBL] [Abstract][Full Text] [Related]
39. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004 [TBL] [Abstract][Full Text] [Related]
40. The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. Derici U; Goker B; Ayerden-Ebinc F; Altok KR; Erten Y; Haznedaroglu S; Aydin M; Arinsoy T; Sindel S Int J Tissue React; 2005; 27(2):69-73. PubMed ID: 16035651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]